Printer Friendly

BIOPLASTY ANNOUNCES STOCK DIVIDEND

 BIOPLASTY ANNOUNCES STOCK DIVIDEND
 ST. PAUL, Minn., Jan. 23 /PRNewswire/ -- The Board of Directors of


Bioplasty, Inc. (NASDAQ: BIOP) announced today that effective immediately Bioplasty would transfer its urological business to a separate corporation and then distribute the shares of that corporation to Bioplasty shareholders as a stock dividend.
 The separate corporation will be named Uroplasty, Inc. The Bioplasty, Inc. directors stated that they intend to distribute the shares of Uroplasty, Inc. as a stock dividend to the Bioplasty, Inc. shareholders on a one-for-one pro rata basis. Such distribution will be made after the Uroplasty stock has been registered with state and federal securities officials. The record date, the payable date and the "ex-date" for the stock dividend will be announced as soon as they are determined.
 The reason for separating the Uroplasty portion of Bioplasty's business is to allow each company to focus on its specific medical market.
 On two previous occasions, Bioplasty has made a stock dividend/spin-off of one of its divisions (Bio-Vascular, Inc. in 1985 and Genetic Laboratories Wound Care, Inc. in 1988).
 The urological portion of Bioplasty's business accounted for less than one percent of sales in fiscal 1991. Bioplasty will transfer to the new corporation net assets ranging from $2 to $3 million. The assets transferred will include the rights to manufacture and distribute Uroplastique(TM).
 -0- 1/23/92
 /CONTACT: Arthur A. Beisang or Timothy P. Lawin of Bioplasty, 612-636-4112/
 (BIOP) CO: Bioplasty, Inc. ST: Minnesota IN: MTC SU: DIV


AL -- MN008 -- 2760 01/23/92 11:36 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 23, 1992
Words:256
Previous Article:GATX ANNOUNCES YEAR-END AND FOURTH QUARTER RESULTS; SECOND MOST PROFITABLE YEAR; EXPECT LOWER 1992 EARNINGS
Next Article:LINCOLN-MERCURY REPORTS SALES
Topics:


Related Articles
BIOPLASTY, INC., ANNOUNCES RECEIPT OF PATENT INFRINGEMENT COMPLAINT
BIOPLASTY RECEIVES BREAST IMPLANT PATENT
FDA CALLS FOR A UNITED STATES MORATORIUM ON SILICONE GEL-FILLED BREAST IMPLANTS
BIOPLASTY PURSUES U.S. REGULATORY APPROVAL FOR UROPLASTIQUE(TM) FOR THE TREATMENT OF URINARY INCONTINENCE
BIOPLASTY SUBMITS INVESTIGATIONAL DEVICE EXEMPTION (IDE) FOR ITS MISTI GOLD BREAST IMPLANTS
UROPLASTY ANNOUNCES APPOINTMENT OF PRESIDENT AND CHIEF EXECUTIVE OFFICER
BIOPLASTY WITHDRAWS SUBMISSIONS FILED WITH FOOD AND DRUG ADMINISTRATION
BIOPLASTY WITHDRAWS BREAST IMPLANTS OVERSEAS
BIOPLASTY ANNOUNCES APPROVAL OF MERGER WITH BIO-MANUFACTURING
BIOPLASTY ANNOUNCES THIRD QUARTER RESULTS OF OPERATIONS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters